The Food and Drug Administration has approved ensitrelvir for the prevention of COVID-19 in individuals aged 12 years and older following exposure to SARS-CoV-2. According to the manufacturer, the authorization makes ensitrelvir the first oral antiviral available in the United States for postexposure prophylaxis against COVID-19. It must be initiated within 72 hours of exposure, and treatment includes a 5-day regimen. Approval was supported by findings from a trial including more than 2,000 participants that …
Read More